FDA Biomarker Program Needs Overhaul, Genentech Says
This article was originally published in The Gray Sheet
Outside experts could provide 'consultation and advice' to sponsors developing qualification plans and to FDA in evaluating qualification submissions.
You may also be interested in...
FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.